Haemate P

Haemate P is a concentrate for solution for injection that contains human coagulation factor VIII and human von Willebrand factor. It is supplied in a sterile liquid form for intravenous administration and is prescribed in the European market. The product provides replacement therapy for patients with deficiencies of factor VIII and von Willebrand factor, supporting the intrinsic coagulation pathway and platelet adhesion to achieve hemostasis.

Haemate P is indicated for the management of bleeding disorders that involve a deficiency of factor VIII, von Willebrand factor, or both.

- Treatment of hemophilia A patients with severe or moderate factor VIII deficiency. - Management of von Willebrand disease type 3 and other severe von Willebrand disease forms. - Control of acute bleeding episodes in individuals with combined factor VIII/von Willebrand factor deficiency. - Perioperative prophylaxis to prevent surgical or dental bleeding in affected patients. - Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in hemophilia A.

Adverse reactions reported with Haemate P reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common: - Mild infusion‑related reactions such as headache, nausea, chills, or low‑grade fever. - Transient elevation of liver enzymes (ALT/AST) that typically resolves without intervention. - Localized pain, swelling, or erythema at the injection site. - Mild allergic manifestations including urticaria, pruritus, or flushing.

Serious: - Anaphylactic or severe hypersensitivity reactions requiring emergency medical treatment. - Development of neutralizing inhibitors against factor VIII, which may reduce therapeutic efficacy. - Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism, especially in patients with additional risk factors. - Potential transmission of blood‑borne pathogens despite rigorous donor screening and viral inactivation steps.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe use.

- Assess for a history of inhibitors to factor VIII before initiating therapy. - Verify negative screening for blood‑borne infections (HIV, hepatitis B/C) in the product batch. - Use caution in patients with a known hypersensitivity to plasma‑derived proteins. - Monitor for signs of thrombosis, especially in individuals with cardiovascular risk factors. - Adjust dosing in patients with renal or hepatic impairment as clinical judgment dictates. - Avoid use in patients with uncontrolled hypertension or active disseminated intravascular coagulation.

Haemate P may interact with other agents that affect coagulation or immune response.

Avoid: - Concurrent use of other activated clotting factor concentrates without medical supervision. - Administration of high‑dose pro‑coagulant agents (e.g., recombinant factor VIIa) in the same treatment episode.

Use with caution: - Antifibrinolytic drugs such as tranexamic acid, which can increase clot stability. - Immunosuppressive therapies that may alter inhibitor development risk. - Concomitant anticoagulants (e.g., warfarin, direct oral anticoagulants) that could counteract hemostatic effect. - Vaccines or biologics administered shortly before or after infusion, which might affect immune response.